ATP Activates Regulatory T Cells In Vivo during Contact Hypersensitivity Reactions

Sabine Ring, Alexander H. Enk and Karsten Mahnke

J Immunol 2010; 184:3408-3416; Prepublished online 5 March 2010;
doi: 10.4049/jimmunol.0901751
http://www.jimmunol.org/content/184/7/3408

Supplementary Material
http://www.jimmunol.org/content/suppl/2010/03/03/jimmunol.0901751.DC1

References
This article cites 43 articles, 21 of which you can access for free at:
http://www.jimmunol.org/content/184/7/3408.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
ATP Activates Regulatory T Cells In Vivo during Contact Hypersensitivity Reactions

Sabine Ring, Alexander H. Enk, and Karsten Mahnke

CD4⁺CD25⁺Foxp3⁺ regulatory T cells (Tregs) require activation to develop their full suppressive capacity. Similar to conventional T cells, Tregs can be activated via their TCRs; however, other means may be in place. We injected naive and nonactivated Tregs, being CD69⁺CD44lowCD62L⁺ into mice, and analyzed their phenotype after sensitization or challenge with the contact sensitizer 2,4,6-trinitro-1-chlorobenzene. We found that Tregs acquired an activated phenotype (CD69⁺CD44hiCD62L⁻) in the draining lymph node after sensitization. In contrast, Ag challenge activated Tregs in the blood. This tissue-specific activation was induced by ATP, which was released at the respective tissue sites after sensitization or challenge, respectively. To demonstrate that activation was also essential for the induction of the suppressive function of Tregs, Tregs were treated with ATP receptor antagonists. In this study, we show that ATP receptor antagonists abrogated the suppressive effects of injected naive Tregs in contact hypersensitivity reactions. Thus, these data indicate that activation of Tregs via ATP in vivo provides a novel pathway of stimulating the suppressive function of Tregs. The Journal of Immunology, 2010, 184: 3408–3416.

Naturally occurring CD4⁺CD25⁺Foxp3⁺ regulatory T cells (Tregs) are able to suppress proliferation of effector T cells and are essential for the maintenance of peripheral tolerance. Their regulatory function has been investigated during autoimmunity, tumor growth, and graft-versus-host disease; however, the underlying mechanisms of action are still not completely understood (1). For instance, several in vitro studies demonstrate the necessity of cell-to-cell contact of Tregs and effector T cells to convey suppressive action (2, 3). In contrast, under in vivo conditions, soluble factors seem to play a role, as release of IL-10 and IL-35 and secretion of TGF-β are crucially attributed to the suppressive effects (4–6).

Irrespective of the mode of action, it has been shown that Tregs require activation to act suppressive. In in vitro suppression assays, the activation is accomplished by cultivating Tregs with APCs together with anti-CD3 Abs or by incubating Tregs with a mixture of anti-CD3 and anti-CD28 Abs, respectively. These experimental settings mimic engagement of the TCR together with activation of coreceptors and trigger full activation of Tregs. Likewise in vivo, MHC–peptide complexes presented by professional APCs engage the TCR and activate Tregs in vivo. Because the TCR is specific for defined MHC–peptide complexes, this mechanism would imply that primarily Tregs, which express the matching Ag-specific TCRs become activated by APCs.

However, this pathway may not be exclusive, as previous results have shown that injection of freshly isolated and thus nonactivated Tregs into 2,4,6-trinitro-1-chlorobenzene (TNCB)-sensitized mice suppressed the ear-swelling reaction, which was induced after reapplication (challenge phase) of the Ag (7, 8). These data suggest that polyclonal, nonactivated Tregs become activated in vivo after application of contact sensitizers like TNCB.

To investigate the underlying mechanisms of the activation of Tregs, we first activated Tregs in vitro by anti-CD3/anti-CD28 Abs and showed upregulation of CD69, CD44, and CD73, indicating activation of the Tregs. Similar results were obtained in vivo. After injection of naive, dye-labeled Tregs into sensitized mice, we assessed the activation status of the labeled Tregs after sensitization or challenge. In this study, we show that CD69 and CD44 were upregulated, and simultaneously, CD62L was downregulated, indicating activation of Tregs. As a possible means of this activation, we identified ATP. ATP acts as a potent activator of Tregs and is produced at the tissue sites upon sensitization or challenge. Notably, blocking of ATP receptor(s) on Tregs abrogated their suppressive function in vivo. Thus, our data indicate that naive Tregs become activated in vivo during contact hypersensitivity (CHS) responses via ATP, which is released at the sites of hapten application.

Materials and Methods

Mice

BALB/c mice were purchased from Charles River Laboratories (Sulzfeld, Germany) and were housed at the central animal facility of the University of Heidelberg (Heidelberg, Germany). All experiments were performed in accordance with the governmental guidelines.

Reagents and Abs

Isolation kits for CD4⁺ T cell and Tregs were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany); anti-CD3 (145-2C11), anti-CD28 (37.51), and all fluorescent-labeled mAb for flow cytometry, except CD39, were obtained from BD Biosciences (Heidelberg, Germany); and PE-Cy7–conjugated anti-mouse CD39 were from eBioscience (San Diego, CA). PKH26 red fluorescent cell linker kit, TNCB, ATP disodium salt (ATP), and pyridoxal phosphate-6-azobenzene-2,4-difluoronic acid) tetrasodium salt hydrate (PPADS) were purchased from Sigma-Aldrich (Taufkirchen, Germany). Luminescence ATP Detection Assay system (APLite) was from PerkinElmer (Waltham, MA). Cell culture medium consisted of RPMI 1640 supplemented with 10% heat-inactivated FCS (both PAA Laboratories, Cölbe, Germany).
Purification of T cell subsets and cell labeling

CD4+ T cell subpopulations were isolated from pooled lymph node (LN) and spleens of naive mice using the “CD4 untouched” magnetic bead separation kit according to the manufacturer’s protocol. To obtain CD4+CD25+ Tregs, the CD4+ T cells were stained with anti-CD25 PE mAb, followed by incubation with anti-PE MicroBeads and passed through separation columns placed in a magnetic field. After removal from the magnetic field, the CD25+ cells were eluted from the column and analyzed by FACS.

The purity of the isolated cell populations ranged from 90 to 95%. The suppressive capacity of the isolated Tregs was always assessed by standard suppression assays.

Freshly isolated Tregs were labeled with the fluorescent dye PKH26, which inserts into the cell membrane. Therefore, 2 × 10^6 serum-free cells were resuspended in 1 ml diluent C before adding 1 ml freshly prepared PKH26 (4 μM). After 3 min of incubation at room temperature, the reaction was stopped by adding 2 ml FCS for 1 min. Thereafter, 4 ml medium was added, and the labeled cells were collected by centrifugation (400 g, 10 min, 25˚C).

In vitro activation of cells

A total of 2 × 10^6 CD4+CD25+ T cells or Tregs were cultured in 200 μl well in 96-well round-bottom plates and stimulated either with anti-CD3 and anti-CD28 (0.5 μg/ml each) or with different amounts of ATP (25, 75, 125, and 200 μM). Activation statuses of the cells were analyzed after 24 h by flow cytometry.

Proliferation assays

Function of ATP preactivated Tregs: CD4+CD25+ T cells and Tregs were stimulated separately with either anti-CD3 and anti-CD28 (0.5 μg/ml each) or ATP (25, 75, 125, and 200 μM) for 24 h. Cells were washed thoroughly and cocultured in different ratios without further stimulation. After 24 h, 0.5 μCi/ml [3H]thymidine was added for 18 h, cells were harvested, and the thymidine incorporation was determined using a PerkinElmer scintillation counter.

Function of anti-CD3/anti-CD28–activated Tregs:CD4+CD25+ T cells and Tregs were cultured in 200 μl well in 96-well round-bottom plates and stimulated either with anti-CD3 and anti-CD28 (0.5 μg/ml each) or with different amounts of ATP (25, 75, 125, and 200 μM). Activation statuses of the cells were analyzed after 24 h by flow cytometry.

Detection of ATP in different organs

Mice were sensitized by painting 15 μl of 1% TNCB dissolved in acetone/olive oil (4:1) or 15 μl solvent only on the shaved abdomen on day 0. On day 5, blank values were determined by measuring the ear thickness using a caliper rule (Oditest, Kroeplin, Schlüchtern, Germany). Afterward, mice were challenged by epicutaneously application of 0.5% TNCB solution, 10 μl on each site of the right ear. The left ear was treated with the same amounts of solvent only. After 24 h, the ear thickness was measured again and difference calculated as: Δ ear response (in mm) = X - Y ± SD.

A total of 3 × 10^4 PKH-PE–labeled Tregs, isolated from LN and spleens of naive mice, were injected either 2 h before sensitization or 15 min before challenge of the mice. For the ATP receptor blocking experiments, Tregs were preincubated with 20 μM PPADS for 2 h before injection.

Mice were sacrificed 24 h after Treg injection, and activation statuses of the Tregs were analyzed in the cell suspension of different organs by flow cytometry.

Results

Tregs constitutively express ectonucleotidases CD39 and CD73 become activated by ATP in vitro

Recent results show that Tregs produce immunosuppressive adenosine via the ectonucleotidases CD39 and CD73 (8–11). Therefore, as indicated and stimulated with anti-CD3 and anti-CD28 (0.5 μg/ml each). After 2–3 d, 0.5 μCi/ml [3H]thymidine was added for 18 h, cells were harvested, and the thymidine incorporation was determined.

Detection of ATP in different organs

Mice were sensitized or sensitized and challenged, control mice were left untreated. Cell suspensions were prepared from nondraining (nd) LNs, draining (d)LNs, spleens, and ear tissue, and additionally, serum was taken 24 h after the respective treatment, and the amount of ATP was detected with the ATPlite luminescence assay system. Briefly, cells were cultured in a black 96-well culture plate (2 × 10^3 cells/well; 100 μl serum/well), t-luciferin and luciferase were added and produced a luminescent signal, caused by the reaction of ATP with t-luciferin and luciferase, which was measured in the MicroBeta TriLux from PerkinElmer.

FIGURE 1. Uregulation of ectonucleotidases on activated Tregs. A, Tregs and CD4+CD25+ T cells were isolated from LN and spleens of naive mice and stimulated with anti-CD3 and anti-CD28 (0.5 μg/ml each) or left untreated (unstimulated). Different activation markers were analyzed by flow cytometry after 24 h of stimulation. B, Expression of ectonucleotidases CD39 and CD73 on Tregs and on CD4+CD25+ T cells treated like described in A. Data show the means ± SD from five independent experiments. Significant differences (*p < 0.001) between unstimulated and anti-CD3/CD28–treated cells were determined by Student t test.
we set out to investigate whether activation of Tregs regulates surface expression of these enzymes, which are crucial for adenosine production. We cultured isolated Tregs and conventional CD4⁺CD25⁻ T cells overnight with anti-CD3/anti-CD28 Abs and show that activation markers, such as CD69 and CD44, were upregulated on both cell types. Likewise, CD62L expression was reduced, indicating successful activation of the T cells (Fig. 1A).

Expression of the ectonucleotidases CD39 as well as CD73 was not upregulated on conventional CD4⁺CD25⁻ T cells upon activation and remained low, with approximately only 20% of the cells being positive for CD39 and CD73 (Fig. 1B). In contrast, ~100% of the Tregs stably expressed both markers, irrespective of whether the cells were activated with Abs or left untreated. However, the mean fluorescence intensity (MFI) of CD73 significantly increased after activation indicating an upregulation of this molecule, whereas the mean fluorescence of CD39 remained stable (data not shown).

Because ATP serves as substrate for adenosine production via the CD39/CD73 cascade, we next asked whether ATP itself exerts stimulatory activity on Tregs. Therefore, we cultured Tregs and conventional T cells overnight with graded doses of ATP and determined the surface expression of respective activation markers. As shown in Fig. 2A, Tregs became activated by ATP in a dose-dependent manner, as indicated by the upregulation of CD69 and CD44 and downregulation of CD62L. Of note, expression of CD73 was very sensitive to ATP as 25 μM, which was not able to substantially increase CD69 expression, was readily able to induce profound CD73 expression (Fig. 2A, Supplemental Fig. 1). However, similar to results obtained with anti-CD3/anti-CD28 stimulation, CD39 was unaffected by ATP stimulation (data not shown).

To further investigate whether ATP activation also results in increased suppressive capacity of Tregs, we established a novel suppression assay in which we cocultured anti-CD3/anti-CD28–preactivated responder T cells with differently pretreated Tregs. This assay is devoid of any T cell stimulatory Abs or APCs during the coculture and thus enables us to compare the suppressive capacity of unstimulated with preactivated Tregs. We show (Fig. 2B) that Tregs activated with 125 μM ATP display similar suppressive activity as compared with anti-CD3/anti-CD28–activated Tregs. This suppressive capacity declined when lower concentrations of ATP (25 μM) were used for activation. In contrast, nonactivated Tregs did not suppress the proliferation of prestimulated CD4⁺CD25⁻ responder T cells. Thus, these data indicate that ATP activates Tregs and stimulates their suppressive function in vitro.

Tregs become activated in vivo at different tissue sites during sensitization and challenge

Several therapeutic procedures in animal models use injection of freshly prepared Tregs for the treatment of medical conditions. That raises the question by which means the naive Tregs become activated in vivo.
To first investigate the site of activation of Tregs in vivo during both phases of CHS reactions, we determined the homing of freshly prepared and dye-labeled Tregs during the sensitization phase as well as during the elicitation phase of CHS reactions. In this study, we show (Fig. 3A) that following sensitization of naïve animals injected Tregs mainly accumulated in the dLN, whereas in the spleen and the blood, only reduced numbers of dye-labeled Tregs were detectable. Notably, when the mice were treated with solvent only, the preferential homing of Tregs to dLNs was abolished. Thus, these data indicate that hapten application drives Treg migration to dLNs.

Analyzing the activation status of the Tregs before and after injection by measuring the expression of respective markers CD69, CD62L, and CD44, we detected that directly after isolation from naïve mice, only 12.8% of the Tregs expressed CD69 (Fig. 3B). Therefore, the cells can be considered as “nonactivated.” These cells were injected into mice, which were subsequently treated with hapten or with solvent only. After 24 h, blood, spleen, and dLN were analyzed for presence of dye-labeled Tregs, and their activation status was reassessed by flow cytometry. As shown in Fig. 3C, the number of activated, CD69+ Tregs was greatly enhanced in the dLN of sensitized mice. Concomitantly, expression of CD62L was downregulated, and the MFI of CD44 was increased (Fig. 3C), indicating an activated phenotype of Tregs. In contrast, Tregs detected in spleens or blood displayed no signs of activation. Likewise, Tregs in “solvent only”-treated mice showed no signs of activation in each of the organs investigated and displayed similar activation levels as compared with “before”

**FIGURE 3.** During the sensitization phase of CHS reactions, Tregs get activated in the dLN. Tregs were isolated from LN and spleen of naïve mice, labeled with PKH-PE, analyzed by flow cytometry, and injected i.v. into naïve mice (3 x 10^6 cells/mouse). Two hours after injection, one experimental group was sensitized with 1% TNCB, and the other group was treated with solvent only. After 24 h, cell suspensions of dLN, spleen, and blood were prepared and analyzed. A, Numbers of immigrated injected PKH-PE+ Tregs in the different organs. Data show the mean of PKH-PE+ cells in percent of CD4+ cells ± SD of three independent experiments (p < 0.001). B, Freshly isolated, PKH-PE–labeled cells were stained with anti-CD69, anti-CD62L, or anti-CD44 and examined by flow cytometry. Dot plots show the expression of the respective markers and numbers given in each dot plot indicates the percentages of CD69+ or CD62L+ cells or the MFI of CD44. C, Expression of CD69, CD62L, and MFI of CD44 on the injected Tregs in the different organs of the two experimental groups. Data show the mean of percentage of positive cells or of the MFI, respectively, ± SD of three independent experiments. Significant differences (p < 0.001) between solvent-treated and TNCB-treated groups were determined by Student t test.
injection. Thus, these data indicate that Tregs become activated in vivo in the dLN during sensitization.

To investigate the effect of the challenge phase on the homing and the activation status of Tregs, freshly isolated and dye-labeled Tregs were injected into sensitized mice, which were challenged 15 min later. Fig. 4A shows that Tregs were primarily detected in the blood, and only declining numbers of Tregs migrated into the spleen and dLN. In contrast, after omitting the challenge (solvent only group), no accumulation of Tregs in the blood could be observed, and Tregs were nearly equally distributed among dLN, spleen, and blood (Fig. 4A).

Thereafter, we also assessed whether the activation status of the Tregs changed in vivo after Ag challenge in the different organs. In this study, we show that Tregs upregulated CD69 expression most vigorously in the blood (Fig 4C), whereas in dLN and spleens only modest expression occurred. In parallel, downregulation of CD62L and upregulation of CD44 were recorded exclusively in blood-derived Tregs (Fig. 4C), indicating that only Tregs in the blood become activated by the challenge reaction. Treatment of the mice with solvent only did not result in activation of the Tregs in the respective organs. In aggregate, these data indicate that Tregs upregulate markers, which are indicative for activation during the sensitization phase of CHS reactions in the dLN. In contrast, during the elicitation phase, activation of Tregs is exclusively detected in the blood.

As activation of T cells may also result in T cell proliferation, we determined the proliferation of CFSE-labeled Tregs in vivo in the sensitization and challenge phase (Supplemental Fig. 3). We observed approximately one round of proliferation in 5–10% of the injected Tregs in dLN (10% of the cells) and in spleens (5% of the cells). However, this proliferation was neither specific for Tregs...
(as control CD4⁺CD25⁻ T cells proliferated to a similar extend) nor dependent on elevated ATP levels (as proliferation also took place during challenge in the dLN, which does not display increased ATP content after challenge). Thus, we conclude that ATP does not drive proliferation of Tregs in vivo, and the insignificant proliferation is induced by hapten application to the skin.

**ATP is elevated in dLN after sensitization and in serum after challenge**

Because we have shown that Tregs become activated in different tissues after sensitization or challenge, respectively, we further hypothesized that ATP release at different body sites may activate Tregs. Therefore, we measured the ATP content of different organs in response to sensitization or challenge.

After sensitization at the ventral abdominal skin (Fig. 5A), ATP levels were significantly elevated in the respective dLN, whereas the serum, the spleen (data not shown), and distant ndLN, such as the mandibular LN, displayed control levels of ATP. By contrast, challenging the mice with hapten at the ear resulted in augmented levels of ATP in serum, whereas ATP remained unaltered in the proper draining and ndLN.

**FIGURE 5.** Increasing amounts of ATP at the site of hapten application in vivo. BALB/c mice were sensitized either on the abdomen (A) or on the ear (B) with 1% TNCB (sensitized), sensitized and challenged 5 d later with 0.5% TNCB (sensitized + challenged) or left untreated (naive). Twenty-four hours after treatment, ndLN, dLN, and serum were taken, and the amounts of ATP were detected with the ATPlite luminescence assay system. Data show the mean of ATP amount in the different organs ± SD of six independent experiments. The significance of differences (*p < 0.01) between the ATP amount in the organs of naive mice and of sensitized or sensitized + challenged mice was determined using the Student t test.

As sensitization and challenge were carried out at different tissue sites (i.e., the abdominal skin and the ear, respectively), we reasoned that the differences in ATP production may be due to different capacities of the tissues to release ATP in response to hapten application. Therefore, we next sensitized mice at one ear and measured the ATP content of the dLN and in the serum. In this study, we show (Fig. 5B) that ATP was only elevated in the respective dLN but not in serum and ndLN, confirming our previous results, showing elevated ATP after sensitization exclusively in the dLN. Likewise, the challenge of these ear-sensitized mice yielded results similar to that obtained after abdominal sensitization. That is, after challenge at the ear, we observed augmented ATP in the serum only, whereas the ATP levels in dLN and ndLN remained unaffected. These data indicate that during sensitization ATP is selectively elevated in the proper dLN, independent from the tissue used for sensitization, whereas challenge leads to increased levels of ATP in the serum. To further substantiate the role of ATP during CHS reactions, we systemically applied ATP before sensitization or challenge, respectively, and measured the ear-swelling reaction thereafter (Supplemental Fig. 4). In this study, we show that administration of ATP before challenge lead to a reduced ear-swelling reaction, whereas the sensitization remained unaffected by ATP. These results are in line with our in vivo observation (i.e., elevated levels of ATP in the blood/serum are effective in activating Tregs at vascular sites), which results in blockade of the elicitation of a CHS response. In contrast, the sensitization takes place in dLN, and i.v. injected ATP may not reach the LN residing Tregs. Consequently, activation of the suppressive function of the Tregs is not induced and sensitization takes place.

**Blocking of ATP receptors on Tregs prevents their function in vivo**

Our data suggest that ATP activates Tregs in vivo, which is a prerequisite for their suppressive activity. Therefore, we next wanted to test whether blockade of the ATP receptors on Tregs abrogates their suppressive capacity in vivo. To this end, we tested the recently described ATP receptor antagonist PPADS at first in vitro by incubation of the Tregs with PPADS prior to stimulation with ATP. Fig. 6A shows that this preincubation with PPADS abrogated the ATP-induced upregulation of the activation marker CD69 in Tregs, indicating blockade of activation by ATP. In addition, we performed suppression assays, where control Tregs or Tregs preincubated with PPADS were coincubated with responder T cells in presence of anti-CD3/anti-CD28 Abs. These data show that Tregs activated independently from ATP receptors are still suppressive and that the ATP receptor antagonist PPADS does not abrogate the suppressive function of Tregs unspecifically for example by inducing cells death. It also demonstrates that several redundant mechanisms of Treg activation exist. That is, the blockade of the ATP receptors on the membrane of Tregs abrogates the ATP-induced Treg activation but still leaves the possibility open to activate Tregs by anti-CD3/anti-CD28 via their TCRs.

Because these in vitro assays established the selective function of PPADS, we next investigated the effects of ATP receptor blockade on the activity of Tregs in the CHS model (Fig. 6C, 6D). To this end, we injected normal Tregs or Tregs that had been preincubated with PPADS into mice 2 h before sensitization. Control mice did not receive any cells before sensitization. After 5 d, mice were challenged, and ear swelling was determined. Analysis of the mice showed that blockade of the ATP receptor(s) by PPADS abrogated the suppressive function of the Tregs (Fig. 6C). Similar results were obtained when Tregs were injected before challenging. In
ATP activates regulatory T cells in vivo. Data show the mean of CD69 expression on Treg were stained with activation marker anti-CD69 and analyzed by flow cytometry. Data show the mean proliferation of CD4+CD25 T cells stimulated with Tregs or Tregs, which were preincubated with PPADS (20 μM; 2 h), in the stated ratios and stimulated with anti-CD3 and anti-CD28 (0.5 μg/ml each). After 3 d of culture, 0.5 μCi/ml [3H]thymidine was added for 18 h, cells were harvested, and the thymidine incorporation was determined. Data show the mean proliferation of CD4+CD25 T cells ± SD of four independent experiments. Significant differences (p < 0.001) between the solvent and ATP-treated cells and the cells, which were treated with PPADS prior to the ATP stimulation, were determined using the Student t test. B, Isolated CD4+CD25 T cells were cocultured with Tregs or Tregs, which were preincubated with PPADS (20 μM; 2 h), in the stated ratios and stimulated with anti-CD3 and anti-CD28 (0.5 μg/ml each). After 24 h of stimulation, Tregs were stained with activation marker anti-CD69 and analyzed by flow cytometry. Data show the mean of CD69 expression on Treg ± SD of four independent experiments. The significance of differences (p < 0.001) between the solvent and ATP-treated cells and the cells, which were treated with PPADS prior to the ATP stimulation, were determined using the Student t test. C, Treg sensitization → challenge → ear swelling. D, sensitization → Treg → challenge → ear swelling. ATP is widely known for its role as energy carrier in almost all cells. However, increasing evidence established that ATP also acts as a second messenger during inflammatory and allergic diseases (12, 13). In line with these observations, our report shows that ATP is able to activate Tregs and to increase their suppressive capacity. We further show in a model of murine cutaneous hypersensitivity (CHS) that application of hapten(s) to the ventral skin of mice (sensitization phase) augments ATP concentrations exclusively in skin dLNs, resulting in activation of naive Tregs. On the contrary, application of the hapten in a challenge reaction augments ATP content primarily in the serum. As a consequence, during sensitization, Tregs become activated in the dLN, whereas Ag challenge activates Tregs in the blood. Thus, these data indicate that ATP may act as a tissue site-specific activator of the suppressive capacity of Tregs in vivo.

It has been established that Tregs require activation to convey their suppressive capacity. Similar to conventional T cells, Tregs harbor a functional TCR and engagement of the TCR by respective MHC–peptide complexes, together with IL-2/IL-4 secretion, are able to induce activation of the suppressor function (3). However, recent results by Szymczak-Wortmann et al. (14) indicate that Tregs do not need to be activated through their TCRs. Our results corroborate these findings and describe a novel pathway of Treg activation by ATP, which is able to augment and/or to induce Treg-mediated suppression during inflammatory responses, independently from the specificity of the TCR(s) expressed by the Tregs. Although the exact means of ATP signaling in Tregs are not clear yet, ATP normally conveys its effects via a multitude of P2x and P2y receptors (12, 15). Both receptor types convey intracellular signaling by different means (i.e., the P2x receptors are ionotropic, and the P2y receptors are G-protein coupled). Especially the role of P2x receptors in signaling in T lymphocytes has been investigated, and recent results indicate that CD4+ effector T cell activation is maintained by binding of autocrinely produced ATP to P2x receptors (16, 17). Moreover, ATP induces a calcium influx in leukocytes by binding to a P2x family receptor. This ATP-induced calcium influx may then provide an interconnection where TCR- and ATP-induced T cell activation join a common pathway, because the “classical” TCR activation also induces elevated calcium levels, which are essential for further downstream signaling resulting in T cell activation. It has also been established that cytokines, such as IL-2, IL-4, IL-7, and IL-15, which trigger the common γ-chain and thus activate PI3K/akt, are crucial for maintaining the suppressive function of Tregs (18, 19). Likewise, ATP receptors have been shown to interfere with the PI3K pathway, because the “classical” TCR activation also induces elevated calcium levels, which are essential for further downstream signaling resulting in T cell activation. It has also been established that cytokines, such as IL-2, IL-4, IL-7, and IL-15, which trigger the common γ-chain and thus activate PI3K/AKT, are crucial for maintaining the suppressive function of Tregs (18, 19). Likewise, ATP receptors have been shown to interfere with the PI3K pathway.
P2X7-triggered calcium influx is crucially involved in decision making on whether activation or death of the respective T cells is triggered also “dampening” of activation, to prevent overboarding from the “danger signal” ATP and simultaneously produce immunosuppressive adenosine by Tregs in the blood, bypassing the necessity for Tregs to home to inflamed tissues for restraining inflammation. So far ATP has predominantly been attributed to proinflammatory actions, but in this study, we present novel data indicating that ATP induces also anti-inflammatory pathways by activating Tregs. This activation of counterbalancing mechanisms is typical for any homeostatic system, in which “activating” signals simultaneously trigger also “dampening” of activation, to prevent overboarding inflammation. In line with these anti-inflammatory functions, ATP has been shown to shift the development of dendritic cells into a TH2 T cell-inducing and thus less proinflammatory phenotype (11, 40). ATP also tightens the junctional permeability during acute lung injury (41), and high concentrations of it induce apoptosis in intestinal CD8+ T cells (42). Moreover, free ATP in tissues is rapidly degraded to adenosine, which has profound inhibitory effects on several immune reactions (43). Our report showing activation of Tregs by ATP adds a novel mechanism to the anti-inflammatory action of ATP and its metabolites. According to our data, ATP may possess a dual function during interaction with Tregs: 1) Tregs become activated by exposure to ATP leading to development of the full arsenal of inhibitory mechanisms, and 2) activated Tregs show enhanced activity of CD39/CD73 ectonucleotidases, resulting in augmented adenosine generation. As a consequence, Tregs clear the tissue environment from the “danger signal” ATP and simultaneously produce a metabolite (i.e., adenosine) with strong anti-inflammatory effects.

In conclusion, our data define a novel pathway of Treg activation, and directed manipulation of ATP/adenosine interaction with Tregs may provide a novel tool to tune the suppressive capacity of Tregs during autoimmune and allergic diseases.

Acknowledgments
We thank Marianne Thome for excellent technical help.

Disclosures
The authors have no financial conflicts of interest.
ATP ACTIVATES REGULATORY T CELLS IN VIVO


